Advertisement

Demyelinating Disease and Pregnancy

  • Tamara B. KaplanEmail author
  • Riley Bove
Chapter

Abstract

Multiple Sclerosis (MS) and Neuromyelitis Optica (NMO) are chronic inflammatory disorders of the central nervous system that often affect women during their childbearing years. Therefore, many patients and providers navigate pregnancy-related management decisions. The current review provides updated information on the clinical effects of pregnancy on MS and NMO course, as well as the available data on safety of immunomodulatory MS treatments for pregnant and lactating women. We also address broader management issues of women with MS and NMO during conception, gestation and the postpartum period.

Keywords

Multiple sclerosis Neuromyelitis optica Demyelinating disease Relapse Disease modifying therapy Pregnancy  Lactation Disability 

References

  1. 1.
    Bove R, Chitnis T. The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis. Mult Scler J. 2014;20(5):520–6.CrossRefGoogle Scholar
  2. 2.
    Hellwig K, Correale J. Artificial reproductive techniques in multiple sclerosis. Clin Immunol. 2013;149(2):219–24.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Visser JA, Schipper I, Laven JS, Themmen AP. Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency. Nat Rev Endocrinol. 2012;8(6):331–41.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Thöne J, Kollar S, Nousome D, et al. Serum anti-Müllerian hormone levels in reproductive-age women with relapsing–remitting multiple sclerosis. Mult Scler J. 2015;21(1):41–7.CrossRefGoogle Scholar
  5. 5.
    Grinsted L, Heltberg A, Hagen C, Djursing H. Serum sex hormone and gonadotropin concentrations in premenopausal women with multiple sclerosis. J Intern Med. 1989;226(4):241–4.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Bove R, Alwan S, Friedman JM, et al. Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review. Obstet Gynecol. 2014;124(6):1157–68.CrossRefGoogle Scholar
  7. 7.
    Cavalla P, Rovei V, Masera S, et al. Fertility in patients with multiple sclerosis: current knowledge and future perspectives. Neurol Sci. 2006;27(4):231–9.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Harward L, Mitchell K, Pieper C, Copland S, Criscione-Schreiber L, Clowse M. The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease. Lupus. 2013;22(1):81–6.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Demirkiran M, Sarica Y, Uguz S, Yerdelen D, Aslan K. Multiple sclerosis patients with and without sexual dysfunction: are there any differences? Mult Scler J. 2006;12(2):209–11.CrossRefGoogle Scholar
  10. 10.
    Dahl J, Myhr K-M, Daltveit A, Hoff J, Gilhus N. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. Neurology. 2005;65(12):1961–3.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    van der Kop ML, Pearce MS, Dahlgren L, et al. Neonatal and delivery outcomes in women with multiple sclerosis. Ann Neurol. 2011;70(1):41–50.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Beecham AH, Patsopoulos NA, Xifara DK, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013;45(11):1353.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Didonna A, Oksenberg JR. Genetic determinants of risk and progression in multiple sclerosis. Clin Chim Acta. 2015;449:16–22.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Langagergaard V, Pedersen L, Gislum M, Nørgard B, Sørensen HT. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a Danish nationwide cohort study. Aliment Pharmacol Ther. 2007;25(1):73–81.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Ascherio A, Munger KL, Lünemann JD. The initiation and prevention of multiple sclerosis. Nat Rev Neurol. 2012;8(11):602–12.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Munger KL, Åivo J, Hongell K, Soilu-Hänninen M, Surcel H-M, Ascherio A. Vitamin D status during pregnancy and risk of multiple sclerosis in offspring of women in the Finnish maternity cohort. JAMA Neurol. 2016;73(5):515–9.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    ACOG Committee on Obstetric Practice. Vitamin D: screening and supplementation during pregnancy. Committee opinion no. 495. Obstet Gynecol 2011;118:197–198.Google Scholar
  18. 18.
    Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T, Group PiMS. Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med. 1998;339(5):285–91.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Vukusic S, Hutchinson M, Hours M, et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain. 2004;127(6):1353–60.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Salemi G, Callari G, Gammino M, et al. The relapse rate of multiple sclerosis changes during pregnancy: a cohort study. Acta Neurol Scand. 2004;110(1):23–6.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Hanulíková P, Vlk R, Meluzínová E, et al. Pregnancy and multiple sclerosis-outcomes analysis 2003–2011. Ceska Gynekol/Ceska Lekarska Spolecnost J Ev Purkyne. 2013;78(2):142–8.Google Scholar
  22. 22.
    Runmarker B, Andersen O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain. 1995;118(1):253–61.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Stenager E, Stenager E, Jensen K. Effect of pregnancy on the prognosis for multiple sclerosis. A 5-year follow up investigation. Acta Neurol Scand. 1994;90(5):305–8.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Mueller BA, Zhang J, Critchlow CW. Birth outcomes and need for hospitalization after delivery among women with multiple sclerosis. Am J Obstet Gynecol. 2002;186(3):446–52.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Dwosh E, Guimond C, Sadovnick A. Reproductive counselling for MS: a rationale. Int MS J. 2003;10(2):52–9.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Boivin J, Bunting L, Collins JA, Nygren KG. International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod. 2007;22(6):1506–12.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Laplaud D-A, Leray E, Barriere P, Wiertlewski S, Moreau T. Increase in multiple sclerosis relapse rate following in vitro fertilization. Neurology. 2006;66(8):1280–1.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Michel L, Foucher Y, Vukusic S, et al. Increased risk of multiple sclerosis relapse after in vitro fertilisation. J Neurol Neurosurg Psychiatry. 2012;83(8):796–802.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Correale J, Farez MF, Ysrraelit MC. Increase in multiple sclerosis activity after assisted reproduction technology. Ann Neurol. 2012;72(5):682–94.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Hellwig K, Beste C, Brune N, et al. Increased MS relapse rate during assisted reproduction technique. J Neurol. 2008;255(4):592–3.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Hellwig K, Schimrigk S, Beste C, Müller T, Gold R. Increase in relapse rate during assisted reproduction technique in patients with multiple sclerosis. Eur Neurol. 2009;61(2):65–8.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Bove R, Rankin K, Lin C, Zhao C, Correale J, Michel L, Chitnis T. Assisted reproductive technologies and relapse risk: a new case series, and pooled analysis of existing studies. Poster presented at ECTRIMS 2017 Oct 25–28; Paris; 2017.Google Scholar
  33. 33.
    Coyle PK. Management of women with multiple sclerosis through pregnancy and after childbirth. Ther Adv Neurol Disord. 2016;9(3):198–210.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Wundes A, Pebdani RN, Amtmann D. What do healthcare providers advise women with multiple sclerosis regarding pregnancy? Mult Scler Int. 2014;819216.Google Scholar
  35. 35.
    Hatcher SE, Waubant E, Nourbakhsh B, Crabtree-Hartman E, Graves JS. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol. 2016;73(7):790–4.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Novi G, Ghezzi A, Pizzorno M, et al. Dramatic rebounds of MS during pregnancy following fingolimod withdrawal. Neurol-Neuroimmunol Neuroinflammation. 2017;4(5):e377.CrossRefGoogle Scholar
  37. 37.
    Sempere A, Berenguer-Ruiz L, Feliu-Rey E. Rebound of disease activity during pregnancy after withdrawal of fingolimod. Eur J Neurol. 2013;20(8):e109–10.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Thöne J, Thiel S, Gold R, Hellwig K. Treatment of multiple sclerosis during pregnancy–safety considerations. Expert Opin Drug Saf. 2017;16(5):523–34.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Coyle PK, Sinclair S, Scheuerle A, Thorp J, Albano J, Rametta M. Final results from the betaseron (interferon β-1b) pregnancy registry: a prospective observational study of birth defects and pregnancy-related adverse events. BMJ Open. 2014;4(5):e004536.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Thiel S, Langer-Gould A, Rockhoff M, et al. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis—a prospective cohort study from the German multiple sclerosis and pregnancy registry. Mult Scler J. 2016;22(6):801–9.CrossRefGoogle Scholar
  41. 41.
    Amato M, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis. Neurology. 2010;75(20):1794–802.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Boskovic R, Wide R, Wolpin J, Bauer D, Koren G. The reproductive effects of beta interferon therapy in pregnancy a longitudinal cohort. Neurology. 2005;65(6):807–11.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Patti F, Cavallaro T, Fermo SL, et al. Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis? J Neurol. 2008;255(8):1250–3.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H. Disease-modifying drugs for multiple sclerosis in pregnancy a systematic review. Neurology. 2012;79(11):1130–5.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Waubant E, Sadovnick AD. Interferon beta babies. Neurology. 2005;65(6):788–9.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Hale TW, Siddiqui AA, Baker TE. Transfer of interferon β-1a into human breastmilk. Breastfeed Med. 2012;7(2):123–5.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Voskuhl R, Momtazee C. Pregnancy: effect on multiple sclerosis, treatment considerations, and breastfeeding. Neurotherapeutics. 2017;14:1–11.CrossRefGoogle Scholar
  48. 48.
    Fragoso YD, Finkelsztejn A, Kaimen-Maciel DR, et al. Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis. CNS Drugs. 2010;24(11):969–76.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Herbstritt S, Langer-Gould A, Rockhoff M, et al. Glatiramer acetate during early pregnancy: a prospective cohort study. Mult Scler J. 2016;22(6):810–6.CrossRefGoogle Scholar
  50. 50.
    Neudorfer O, Melamed-Gal S, Baruch P. Pregnancy outcomes in patients with multiple sclerosis and exposure to branded glatiramer acetate during all three trimesters. Poster presented at ECTRIMS 2017 Oct 25–28; Paris; 2017.Google Scholar
  51. 51.
    Hellwig K. Pregnancy in multiple sclerosis. Eur Neurol. 2014;72(Suppl. 1):39–42.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Gold R, Phillips JT, Havrdova E, et al. Delayed-release dimethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience. Neurol Ther. 2015;4(2):93–104.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Biogen Idec Inc. Tecfidera, Dimethy; Fumarte package insert. Massachusetts: Biogen Idec; 2014.Google Scholar
  54. 54.
    Almas S, Vance J, Baker T, Hale T. Management of multiple sclerosis in the breastfeeding mother. Mult Scler Int. 2016;2016:6527458.CrossRefGoogle Scholar
  55. 55.
    Karlsson G, Francis G, Koren G, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology. 2014;82(8):674–80.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Houtchens MK, Sadovnick AD. Health issues in women with multiple sclerosis. Springer; 2017.Google Scholar
  57. 57.
    Collins W, Francis G, Koren G, et al. Lack of interaction between fingolimod (FTY720) and oral contraceptives, and pregnancy experience in the clinical program of fingolimod in multiple sclerosis. Paper presented at: Neurology. 2011.Google Scholar
  58. 58.
    Buraga I, Popovici R-E. Multiple sclerosis and pregnancy: current considerations. Sci World J. 2014;513160.Google Scholar
  59. 59.
    Vukusic S, Marignier R. Multiple sclerosis and pregnancy in the ‘treatment era’. Nat Rev Neurol. 2015;11(5):280–9.CrossRefGoogle Scholar
  60. 60.
    Brent Robert L. Teratogen update—reproductive risks of leflunomide (Arava TM); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplanting fathering a child. Teratology. 2001;63:106–12.CrossRefGoogle Scholar
  61. 61.
    Cassina M, Johnson D, Robinson L, et al. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheumatol. 2012;64(7):2085–94.CrossRefGoogle Scholar
  62. 62.
    AUBAGIO prescribing information. Cambridge: Genzyme Corporation, a Sanofi company; 2012. Available from: http://products.sanofi.us/aubagio/aubagio.pdf. Accessed 18 Jan 2018.
  63. 63.
    Biogen Idec Inc. Daclizumab package insert. Massachusetts: Biogen Idec; 2016.Google Scholar
  64. 64.
    Gold R, Stefoski D, Selmaj K, et al. Pregnancy experience: nonclinical studies and pregnancy outcomes in the daclizumab clinical study program. Neurol Ther. 2016;5(2):169–82.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    EMA. Zinbryta® (daclizumab) – EPAR summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003862/WC500210598.pdf.
  66. 66.
    Haghikia A, Langer-Gould A, Rellensmann G, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014;71(7):891–5.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Kümpfel T, Thiel S, Meinl I, Gold R, Hellwig K. Long-term exposure to natalizumab during pregnancy – a prospective case series from the German multiple sclerosis and pregnancy registry. Poster presented at ECTRIMS 2017 Oct 25-28; Paris; 2017.Google Scholar
  68. 68.
    Baker TE, Cooper SD, Kessler L, Hale TW. Transfer of natalizumab into breast milk in a mother with multiple sclerosis. J Hum Lact. 2015;31(2):233–6.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Gelfand JM, Cree BA, Hauser SL. Ocrelizumab and other CD20+ B-cell-depleting therapies in multiple sclerosis. Neurotherapeutics. 2017;14:1–7.CrossRefGoogle Scholar
  70. 70.
    Klink D, Van Elburg R, Schreurs M, Van Well G. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol. 2008;2008(1):1.CrossRefGoogle Scholar
  71. 71.
    Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499–506.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Genentech. Ocrelizumab package insert. San Francisco: Genentech; 2017.Google Scholar
  73. 73.
    Vaidyanathan A, McKeever K, Anand B, Eppler S, Weinbauer GF, Beyer JC. Developmental immunotoxicology assessment of rituximab in cynomolgus monkeys. Toxicol Sci. 2010;119(1):116–25.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Hurley WL, Theil PK. Perspectives on immunoglobulins in colostrum and milk. Nutrients. 2011;3(4):442–74.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Bragnes Y, Boshuizen R, de Vries A, Lexberg Å, Østensen M. Low level of Rituximab in human breast milk in a patient treated during lactation. Rheumatology. 2017;56(6):1047–8.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Oh J, Achiron A, Chambers C, et al. Pregnancy outcomes in patients with RRMS who received alemtuzumab in the clinical development program (S24. 008). Neurology. 2016;86(16 Supplement):S24.008.Google Scholar
  77. 77.
    Bove RM, Klein JP. Neuroradiology in women of childbearing age. Continuum Lifelong Learn Neurol. 2014;20(1):23–41.CrossRefGoogle Scholar
  78. 78.
    Argyriou AA, Makris N. Multiple sclerosis and reproductive risks in women. Reprod Sci. 2008;15(8):755–64.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Fraser F, Sajoo A. Teratogenic potential of corticosteroids in humans. Teratology. 1995;51(1):45–6.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Carmichael SL, Shaw GM. Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet A. 1999;86(3):242–4.CrossRefGoogle Scholar
  81. 81.
    Skuladottir H, Wilcox AJ, Ma C, et al. Corticosteroid use and risk of orofacial clefts. Birth Defects Res A Clin Mol Teratol. 2014;100(6):499–506.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Bjørn A-MB, Ehrenstein V, Hundborg HH, Nohr EA, Sørensen HT, Nørgaard M. Use of corticosteroids in early pregnancy is not associated with risk of oral clefts and other congenital malformations in offspring. Am J Ther. 2014;21(2):73–80.CrossRefGoogle Scholar
  83. 83.
    Achiron A, Kishner I, Dolev M, et al. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol. 2004;251(9):1133–7.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Webb JA, Thomsen HS, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur Radiol. 2005;15(6):1234–40.CrossRefGoogle Scholar
  85. 85.
    ACOG Committee on Obstetric Practice. ACOG committee opinion. number 299, September 2004 (replaces no. 158, September 1995). Guidelines for diagnostic imaging during pregnancy. Obstet Gynecol. 2004;104(3):647.CrossRefGoogle Scholar
  86. 86.
    Milgrom J, Gemmill AW, Bilszta JL, et al. Antenatal risk factors for postnatal depression: a large prospective study. J Affect Disord. 2008;108(1):147–57.PubMedCrossRefGoogle Scholar
  87. 87.
    Feinstein A. Multiple sclerosis and depression. Mult Scler J. 2011;17(11):1276–81.CrossRefGoogle Scholar
  88. 88.
    Langer-Gould A, Beaber BE. Effects of pregnancy and breastfeeding on the multiple sclerosis disease course. Clin Immunol. 2013;149(2):244–50.PubMedCrossRefGoogle Scholar
  89. 89.
    Hellwig K, Rockhoff M, Herbstritt S, et al. Exclusive breastfeeding and the effect on postpartum multiple sclerosis relapses. JAMA Neurol. 2015;72(10):1132–8.CrossRefGoogle Scholar
  90. 90.
    Portaccio E, Ghezzi A, Hakiki B, et al. Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology. 2011;77(2):145–50.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Pakpoor J, Disanto G, Lacey MV, Hellwig K, Giovannoni G, Ramagopalan SV. Breastfeeding and multiple sclerosis relapses: a meta-analysis. J Neurol. 2012;259(10):2246–8.CrossRefGoogle Scholar
  92. 92.
    De Seze J, Chapelotte M, Delalande S, Ferriby D, Stojkovic T, Vermersch P. Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult Scler J. 2004;10(5):596–7.CrossRefGoogle Scholar
  93. 93.
    Cooper SD, Felkins K, Baker TE, Hale TW. Transfer of methylprednisolone into breast milk in a mother with multiple sclerosis. J Hum Lact. 2015;31(2):237–9.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Achiron A, Rotstein Z, Noy S, Mashiach S, Dulitzky M, Achiron R. Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. J Neurol. 1996;243(1):25–8.PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Brandt-Wouters E, Gerlach OH, Hupperts RM. The effect of postpartum intravenous immunoglobulins on the relapse rate among patients with multiple sclerosis. Int J Gynecol Obstet. 2016;134(2):194–6.CrossRefGoogle Scholar
  96. 96.
    Bove R, Rankin K, Chua AS, et al. Oral contraceptives and MS disease activity in a contemporary real-world cohort. Mult Scler J. 2017;  https://doi.org/10.1177/1352458517692420.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Pozzilli C, De Giglio L, Barletta VT, et al. Oral contraceptives combined with interferon β in multiple sclerosis. Neurol-Neuroimmunol Neuroinflammation. 2015;2(4):e120.CrossRefGoogle Scholar
  98. 98.
    Vukusic S, Ionescu I, El-Etr M, et al. The prevention of post-partum relapses with progestin and estradiol in multiple sclerosis (POPART'MUS) trial: rationale, objectives and state of advancement. J Neurol Sci. 2009;286(1):114–8.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Durand-Dubief F, El-Etr M, Ionescu I, et al. The POPARTMUS French-Italian multicentric trial of postpartum progestin and estradiol in multiple sclerosis: MRI findings. Paper presented at: Multiple Sclerosis Journal 2014.Google Scholar
  100. 100.
    Haghmorad D, Amini AA, Mahmoudi MB, Rastin M, Hosseini M, Mahmoudi M. Pregnancy level of estrogen attenuates experimental autoimmune encephalomyelitis in both ovariectomized and pregnant C57BL/6 mice through expansion of Treg and Th2 cells. J Neuroimmunol. 2014;277(1):85–95.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Jansson L, Olsson T, Holmdahl R. Estrogen induces a potent suppression of experimental autoimmune encephalomyelities and collagen-induced arthritis in mice. J Neuroimmunol. 1994;53(2):203–7.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Sicotte NL, Liva SM, Klutch R, et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol. 2002;52(4):421–8.CrossRefGoogle Scholar
  103. 103.
    Voskuhl RR, Wang H, Wu TJ, et al. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(1):35–46.PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Rizvi SA, Bashir K. Other therapy options and future strategies for treating patients with multiple sclerosis. Neurology. 2004;63(12 suppl 6):S47–54.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Lennon VA, Kryzer TJ, Pittock SJ, Verkman A, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473–7.PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Matiello M, Schaefer-Klein J, Sun D, Weinshenker BG. Aquaporin 4 expression and tissue susceptibility to neuromyelitis optica. JAMA Neurol. 2013;70(9):1118–25.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Quek AM, McKeon A, Lennon VA, et al. Effects of age and sex on aquaporin-4 autoimmunity. Arch Neurol. 2012;69(8):1039–43.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Marrie RA, Gryba C. The incidence and prevalence of neuromyelitis optica: a systematic review. Int J MS Care. 2013;15(3):113–8.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012;69(9):1176–80.PubMedCrossRefPubMedCentralGoogle Scholar
  110. 110.
    Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805–15.PubMedCrossRefPubMedCentralGoogle Scholar
  111. 111.
    Pandit L, Asgari N, Apiwattanakul M, et al. Demographic and clinical features of neuromyelitis optica: a review. Mult Scler J. 2015;21(7):845–53.CrossRefGoogle Scholar
  112. 112.
    Klawiter EC, Bove R, Elsone L, et al. High risk of postpartum relapses in neuromyelitis optica spectrum disorder. Neurology. 2017;  https://doi.org/10.1212/WNL.0000000000004681.PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Kim W, Kim S-H, Nakashima I, et al. Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology. 2012;78(16):1264–7.CrossRefGoogle Scholar
  114. 114.
    Fragoso YD, Adoni T, Bichuetti DB, et al. Neuromyelitis optica and pregnancy. J Neurol. 2013;260(10):2614–9.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Nour MM, Nakashima I, Coutinho E, et al. Pregnancy outcomes in aquaporin-4–positive neuromyelitis optica spectrum disorder. Neurology. 2016;86(1):79–87.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Reichlin M. Systemic lupus erythematosus and pregnancy. J Reprod Med. 1998;43:355–60.PubMedPubMedCentralGoogle Scholar
  117. 117.
    Davoudi V, Keyhanian K, Bove RM, Chitnis T. Immunology of neuromyelitis optica during pregnancy. Neurol-Neuroimmunol Neuroinflammation. 2016;3(6):e288.CrossRefGoogle Scholar
  118. 118.
    Reuß R, Rommer PS, Brück W, et al. A woman with acute myelopathy in pregnancy: case outcome. London: BMJ Publishing Group; 2009.Google Scholar
  119. 119.
    Kimbrough DJ, Fujihara K, Jacob A, et al. Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord. 2012;1(4):180–7.PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab. Arch Neurol. 2008;65(11):1443–8.PubMedCrossRefPubMedCentralGoogle Scholar
  121. 121.
    Pellkofer H, Suessmair C, Schulze A, Hohlfeld R, Kuempfel T. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab. Mult Scler J. 2009;15(8):1006–8.CrossRefGoogle Scholar
  122. 122.
    Azim HA Jr, Azim H, Peccatori FA. Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Rev Clin Immunol. 2010;6(6):821–6.PubMedCrossRefGoogle Scholar
  123. 123.
    Prunty M, Sharpe L, Butow P, Fulcher G. The motherhood choice: themes arising in the decision-making process for women with multiple sclerosis. Mult Scler J. 2008;14(5):701–4.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Neurology, Harvard Medical SchoolBrigham and Women’s HospitalBostonUSA
  2. 2.Department of Neurology, Weill Institute for the NeurosciencesUniversity of CaliforniaSan FranciscoUSA

Personalised recommendations